

B-LCL-HROC285 | 300869

Description	B-LCL-HROC285	-	EBV	B		HNPCC	DNA
	B-LCL-HROC285				B	EBV	B

Organism

Tissue

Disease

Metastatic site Not applicable (EBV-transformed B-LCL from Lynch syndrome CRC patient)

Applications T cell and NK cell assays; HLA typing; Lynch syndrome immunology; mismatch repair (MMR) deficiency-associated immune response; CTL assay target cells; HROC biobank patient-matched studies

Synonyms B-LCL CO285 Bc HROC285

Age 30

Gender

Ethnicity

Morphology

Cell type B

Growth properties

Citation B-LCL-HROC285 Cytion 300869

Biosafety level 2

B-LCL-HROC285 | 300869

NCBI_TaxID	9606
-------------------	------

CellosaurusAccession	Not assigned
-----------------------------	--------------

GMO Status	GMO-S2: This B-LCL contains a stably maintained EBV episome (EBNA-1/-2/-3, LMP-1/-2). EBV is classified as risk group 2; BSL-2 containment required. This classification applies within Germany; regulations may differ elsewhere.
-------------------	--

Viruses	EBV
----------------	-----

Culture Medium	RPMI 1640 w 2.0 mM	w 2.0 g/L NaHCO3	Cytion	820700a
-----------------------	--------------------	------------------	--------	---------

Supplements	10%	FBS
--------------------	-----	-----

Subculturing	⁵ /	1×10
---------------------	----------------	------

Freeze medium	FBS +10% DMSO	CM-1 Cytion	800100	CM-1 Cytion	800100
----------------------	---------------	-------------	--------	-------------	--------

Thawing and Culturing Cells	1.			
	2.	-150°C		3
	3.	37°C		40-60
	4.		70%	
	5.	8	15	
	6.	300 x g	3	
	7.	10		T25
				T25
	8.			

B-LCL-HROC285 | 300869

**Incubation
Atmosphere** 37°C, 5% CO₂

Flask Coating

**Freezing
Procedure** -78 °C

**Shipping
Conditions** -78 °C

**Storage
Conditions** -150 -196 -80 °C

/ **/HLA**

Sterility PCR